Teacher Retirement System of Texas Invests $2.77 Million in Clover Health Investments, Corp. (NASDAQ:CLOV)

Teacher Retirement System of Texas acquired a new position in Clover Health Investments, Corp. (NASDAQ:CLOV) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 878,936 shares of the company’s stock, valued at approximately $2,769,000.

Other institutional investors have also added to or reduced their stakes in the company. Steph & Co. lifted its position in shares of Clover Health Investments by 33.3% in the 4th quarter. Steph & Co. now owns 20,000 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. Arizona State Retirement System raised its stake in Clover Health Investments by 6.3% during the fourth quarter. Arizona State Retirement System now owns 118,265 shares of the company’s stock worth $373,000 after buying an additional 6,990 shares during the last quarter. SignalPoint Asset Management LLC lifted its holdings in Clover Health Investments by 6.2% in the fourth quarter. SignalPoint Asset Management LLC now owns 160,074 shares of the company’s stock valued at $504,000 after buying an additional 9,390 shares during the period. Parallax Volatility Advisers L.P. bought a new stake in Clover Health Investments during the third quarter valued at $38,000. Finally, Silverleafe Capital Partners LLC grew its holdings in Clover Health Investments by 182.9% during the 4th quarter. Silverleafe Capital Partners LLC now owns 45,000 shares of the company’s stock worth $142,000 after acquiring an additional 29,091 shares during the period. 19.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CLOV. Craig Hallum assumed coverage on Clover Health Investments in a research report on Tuesday, December 17th. They set a “buy” rating and a $6.00 target price on the stock. Canaccord Genuity Group increased their price target on Clover Health Investments from $4.20 to $4.50 and gave the stock a “buy” rating in a report on Monday, March 3rd.

Insider Activity

In other Clover Health Investments news, General Counsel Karen Soares sold 52,500 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $3.80, for a total value of $199,500.00. Following the transaction, the general counsel now owns 1,299,663 shares in the company, valued at approximately $4,938,719.40. This represents a 3.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brady Patrick Priest sold 75,000 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $3.68, for a total value of $276,000.00. Following the sale, the chief executive officer now owns 2,418,151 shares of the company’s stock, valued at approximately $8,898,795.68. This represents a 3.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 327,500 shares of company stock worth $1,197,500 in the last three months. Company insiders own 22.28% of the company’s stock.

Clover Health Investments Trading Up 1.6 %

CLOV opened at $3.87 on Wednesday. The company has a fifty day moving average price of $4.13 and a two-hundred day moving average price of $3.68. Clover Health Investments, Corp. has a 1-year low of $0.61 and a 1-year high of $4.87. The company has a market cap of $1.98 billion, a P/E ratio of -19.35 and a beta of 2.00.

Clover Health Investments Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.